
@BiotechAutist Considering LAD-1 is ultra - rare lethal disease with currently no approved treatment beyond high risk BM transplant , FDA might tolerate weaker control structure considering RCKT has adequately addressed CMC issue. Might go for post marketing requirement.
English
















